STP 133G
Alternative Names: STP-133GLatest Information Update: 28 Oct 2024
At a glance
- Originator Sirnaomics
- Class Antihyperlipidaemics; Peptide drug conjugates; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Metabolic disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (SC)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (SC)
- 29 Sep 2020 Preclinical trials in Dyslipidaemias in USA (SC) (Sirnaomics pipeline, September 2020)